Benefit-Risk Evaluation of Tolterodine (4 Mg) and Fesoterodine (fixed and Flexible Dosing): Using Multi-criteria Decision Analysis Modelling to Help Physicians Optimise Treatment in Patients Diagnosed with Overactive Bladder